Details of the Drug Combination

General Information of Drug Combination (ID: DCVEPHT)

Drug Combination Name
Hepzato Terameprocol
Indication
Disease Entry Status REF
Non-small cell lung carcinoma Investigative [1]
Component Drugs Hepzato   DM2AZPP Terameprocol   DMC3P45
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: HOP-92
Zero Interaction Potency (ZIP) Score: 1.54
Bliss Independence Score: 4.41
Loewe Additivity Score: 2.55
LHighest Single Agent (HSA) Score: 1

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Hepzato
Disease Entry ICD 11 Status REF
Uveal Melanoma 2D0Y Phase 3 [2]
Indication(s) of Terameprocol
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
Terameprocol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Transcription factor Sp1 (SP1) TTZEP6S SP1_HUMAN Modulator [3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult acute myeloid leukemia DCUD1D2 HL-60(TB) Investigative [4]
Adult T acute lymphoblastic leukemia DC6S3XJ MOLT-4 Investigative [4]
Anaplastic large cell lymphoma DC7DHX3 SR Investigative [4]
Astrocytoma DC4XWNC U251 Investigative [4]
Childhood T acute lymphoblastic leukemia DCFBNEA CCRF-CEM Investigative [4]
Chronic myelogenous leukemia DCK8IHH K-562 Investigative [4]
Clear cell renal cell carcinoma DC74FIE A498 Investigative [4]
Clear cell renal cell carcinoma DCX12ZO CAKI-1 Investigative [4]
Glioblastoma DCVMJY8 SNB-75 Investigative [4]
Glioma DCL6PM8 SF-539 Investigative [4]
Papillary renal cell carcinoma DC0HL1I ACHN Investigative [4]
Plasma cell myeloma DCLI4ZC RPMI-8226 Investigative [4]
Carcinoma DCFCD95 RXF 393 Investigative [5]
Carcinoma DCJAFQX MCF7 Investigative [5]
Colon carcinoma DCHXDHA KM12 Investigative [5]
Invasive ductal carcinoma DCXSO0L HS 578T Investigative [5]
Adenocarcinoma DCRLWII DU-145 Investigative [1]
Adenocarcinoma DCAOI22 OVCAR3 Investigative [1]
Adenocarcinoma DC68ZAG NCIH23 Investigative [1]
Adenocarcinoma DCZ5PNP HCC-2998 Investigative [1]
Adenocarcinoma DCOZG66 HT29 Investigative [1]
Amelanotic melanoma DCOSCEX MDA-MB-435 Investigative [1]
Cutaneous melanoma DCMHZN5 SK-MEL-5 Investigative [1]
High grade ovarian serous adenocarcinoma DCO3U9J OVCAR-8 Investigative [1]
High grade ovarian serous adenocarcinoma DCH88QQ OVCAR-5 Investigative [1]
High grade ovarian serous adenocarcinoma DC7GGYG NCI\\/ADR-RES Investigative [1]
Lung adenocarcinoma DCGA0HM HOP-62 Investigative [1]
Lung adenocarcinoma DC4RH99 EKVX Investigative [1]
Lung adenocarcinoma DC7QPNF NCI-H522 Investigative [1]
Malignant melanoma DCP7VOU UACC62 Investigative [1]
Melanoma DC7ZBXV UACC-257 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 31 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
3 Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.